Novel molecular-targeted treatments show great prospects for radioiodine-refractory and surgically inoperable thyroid carcinomas. While aberrations in protein-coding genes are a focus in molecular thyroid cancer medicine, the impact of oncogenes on the expression of long noncoding RNAs (lncRNAs) has been largely uncharacterized. We aimed to identify the expression patterns of lncRNAs and mRNAs in high-throughput molecular profiles of 18 papillary thyroid cancer (PTC) patients. We identified 452 mRNAs and 240 unannotated lncRNAs that were differentially expressed in PTC. Significantly enriched GO terms and pathways were identified, many of which were linked to cancer. By integrating the predicted lncRNA target genes with differentially expressed mRNAs, we identified 20 candidate lncRNAs in 45 PTC patients. Five lncRNAs (CTD-3193O13.11, RP5-1024C24.1, AC007255.8, HOXD-AS1, and RP11-402L6.1) were verified to be differentially expressed in PTC and to exhibit specific topological characteristics in the lncRNA–mRNA co-expression network. LncRNA CTD-3193O13.11 was determined to comprise a node of co-regulation with the other lncRNAs in PTC tumorigenesis. LncRNA RP5-1024C24.1, AC007255.8, and HOXD-AS1 expression was significantly related to clinical stage, lncRNA RP11-402L6.1 expression was associated with lymph node metastasis, lncRNA CTD-3193O13.11 expression was proportional to tumor size, and lncRNA AC007255.8 expression was proportional to patient age. Therefore, our study provides a genome-wide screening and analysis of lncRNA expression in PTC, which brings novel insights into the roles of lncRNAs in PTC progression.

中文翻译：

---

甲状腺癌中长非编码RNA–mRNA共表达模式的综合分析

新型的分子靶向治疗方法在放射性碘难治性和外科手术无法手术的甲状腺癌中显示出广阔的前景。尽管蛋白质编码基因中的畸变是分子甲状腺癌药物中的重点，但癌基因对长非编码RNA（lncRNA）表达的影响尚未得到充分表征。我们旨在鉴定18例甲状腺乳头状癌（PTC）患者高通量分子谱中lncRNA和mRNA的表达模式。我们鉴定了452个mRNA和240个未注释的lncRNA，它们在PTC中差异表达。确定了大量GO术语和途径，其中许多与癌症有关。通过整合预测的lncRNA靶基因与差异表达的mRNA，我们在45例PTC患者中鉴定出20个候选lncRNA。五个lncRNA（CTD-3193O13.11，RP5-1024C24。1，AC007255.8，HOXD-AS1和RP11-402L6.1）经验证在PTC中差异表达，并在lncRNA-mRNA共表达网络中表现出特定的拓扑特征。确定LncRNA CTD-3193O13.11包含与PTC肿瘤发生过程中其他lncRNA共同调控的一个节点。LncRNA RP5-1024C24.1，AC007255.8和HOXD-AS1的表达与临床分期显着相关，lncRNA RP11-402L6.1的表达与淋巴结转移相关，lncRNA CTD-3193O13.11的表达与肿瘤大小成正比， lncRNA AC007255.8的表达与患者年龄成正比。因此，我们的研究提供了PTC中lncRNA表达的全基因组筛选和分析，这为lncRNA在PTC进展中的作用带来了新见解。1）被证实在PTC中差异表达，并在lncRNA-mRNA共表达网络中表现出特定的拓扑特征。确定LncRNA CTD-3193O13.11包含与PTC肿瘤发生过程中其他lncRNA共同调控的一个节点。LncRNA RP5-1024C24.1，AC007255.8和HOXD-AS1的表达与临床分期显着相关，lncRNA RP11-402L6.1的表达与淋巴结转移相关，lncRNA CTD-3193O13.11的表达与肿瘤大小成正比， lncRNA AC007255.8的表达与患者年龄成正比。因此，我们的研究提供了PTC中lncRNA表达的全基因组筛选和分析，这为lncRNA在PTC进展中的作用带来了新见解。1）被证实在PTC中差异表达，并在lncRNA-mRNA共表达网络中表现出特定的拓扑特征。确定LncRNA CTD-3193O13.11包含与PTC肿瘤发生过程中其他lncRNA共同调控的一个节点。LncRNA RP5-1024C24.1，AC007255.8和HOXD-AS1的表达与临床分期显着相关，lncRNA RP11-402L6.1的表达与淋巴结转移相关，lncRNA CTD-3193O13.11的表达与肿瘤大小成正比， lncRNA AC007255.8的表达与患者年龄成正比。因此，我们的研究提供了PTC中lncRNA表达的全基因组筛选和分析，这为lncRNA在PTC进展中的作用带来了新见解。确定LncRNA CTD-3193O13.11包含与PTC肿瘤发生过程中其他lncRNA共同调控的一个节点。LncRNA RP5-1024C24.1，AC007255.8和HOXD-AS1的表达与临床分期显着相关，lncRNA RP11-402L6.1的表达与淋巴结转移相关，lncRNA CTD-3193O13.11的表达与肿瘤大小成正比， lncRNA AC007255.8的表达与患者年龄成正比。因此，我们的研究提供了PTC中lncRNA表达的全基因组筛选和分析，这为lncRNA在PTC进展中的作用带来了新见解。确定LncRNA CTD-3193O13.11包含与PTC肿瘤发生过程中其他lncRNA共同调控的一个节点。LncRNA RP5-1024C24.1，AC007255.8和HOXD-AS1的表达与临床分期显着相关，lncRNA RP11-402L6.1的表达与淋巴结转移相关，lncRNA CTD-3193O13.11的表达与肿瘤大小成正比， lncRNA AC007255.8的表达与患者年龄成正比。因此，我们的研究提供了PTC中lncRNA表达的全基因组筛选和分析，这为lncRNA在PTC进展中的作用带来了新见解。1表达与淋巴结转移相关，lncRNA CTD-3193O13.11表达与肿瘤大小成正比，lncRNA AC007255.8表达与患者年龄成正比。因此，我们的研究提供了PTC中lncRNA表达的全基因组筛选和分析，这为lncRNA在PTC进展中的作用带来了新见解。1表达与淋巴结转移相关，lncRNA CTD-3193O13.11表达与肿瘤大小成正比，lncRNA AC007255.8表达与患者年龄成正比。因此，我们的研究提供了PTC中lncRNA表达的全基因组筛选和分析，这为lncRNA在PTC进展中的作用带来了新见解。